#USA #Class Action #New Orleans #Kahn Swick #Soleno Therapeutics

Important Announcement for Soleno Therapeutics Investors

A recent notice from Kahn Swick & Foti, LLC (KSF), a prominent securities litigation law firm, highlights a critical deadline for investors of Soleno Therapeutics, Inc. The firm, led by former Louisiana Attorney General Charles C. Foti, Jr., is reaching out to individuals affected by alleged securities fraud involving Soleno. Investors are urged to act swiftly as the deadline for submitting applications to be appointed as lead plaintiffs is set for May 5, 2026.

Background of the Case

The class action lawsuit focuses on claims against Soleno Therapeutics concerning financial disclosures made between March 26, 2025, and November 4, 2025. Investors allege that the company and certain executives failed to disclose essential information that may have influenced their investment decisions. Key allegations include the misrepresentation of safety concerns related to DCCR, Soleno's primary product used to treat hyperphagia in patients with Prader-Willi syndrome (PWS).

Allegations of Securities Fraud

The lawsuit outlines several serious allegations:
1. The Phase 3 clinical trials for DCCR allegedly mischaracterized and minimized safety concerns, including potential excessive fluid retention among participants.
2. These purported failures mean that DCCR presented greater safety risks than disclosed, impacting its perceived viability in the market.
3. Investors argue that due to the underreported risks, the product may face issues related to patient adoption and potential legal repercussions after its launch.

What Investors Should Do

If you invested in Soleno and experienced a financial loss during the specified period, you have the opportunity to seek justice. You do not need to serve as the lead plaintiff to claim your portion of any recovery, but you must ensure your application is submitted to the court by the deadline. Interested parties can reach out to Kahn Swick & Foti for more information and assistance with their claims. They can be contacted directly through the following options:

• - Phone: 1-877-515-1850
• - Email: email protected]
• - Website: [Kahn Swick & Foti

About Kahn Swick & Foti, LLC

Founded by notable figures including Charles C. Foti, Jr., KSF is recognized as one of the leading boutique law firms specializing in securities litigation. Recently, KSF achieved recognition as one of the top firms nationally based on settlement values, indicating their commitment to recovering losses for public and private investors affected by corporate fraud. The firm's legal team operates out of various offices, including locations in New York, Louisiana, and California, ensuring that they are accessible to clients nationwide.

Conclusion

The May 5, 2026, application deadline for the class action lawsuit regarding Soleno Therapeutics represents a significant opportunity for affected investors. It is crucial to act promptly and gather any necessary documentation that may support your claim. With the potential complexity of legal proceedings, engaging with a knowledgeable firm like KSF can provide the guidance needed to navigate this challenging situation. Don’t miss your chance to be a part of this class action;
for further inquiries, connect with Kahn Swick & Foti today.